Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.


Ozen M., Aksoy S., Dizdar O., Dede D. S., Dogan E., Arslan C., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.28, sa.15, 2010 (SCI-Expanded) identifier